CD8A and neoplasm: Because targeting of IL-17A lowered PDL1 expression in tumor tissues and promoted the T cell response, especially of CD8+ T cells, in tumor-bearing mice, we next sought to determine whether antitumor immunity could be established by anti-IL-17A injection.